Summarized by Masters of Longevity from Longevity Technology.
Report summarizing key scientific, regulatory, commercial and investor discussions at a major aging research and drug development meeting moved to a larger US venue.
Key Takeaways
- ARPA-H announced PROSPR, a $144 million five-year program to build trial infrastructure for preventive aging therapeutics.
- Regulators signaled approvable pathways will target prevention of age-related comorbidities or mortality using longer controlled trials with hard endpoints.
- Industry presented biological-age data on GLP-1 drugs, with semaglutide modeled to add 1.9 average years and tirzepatide slowing epigenetic aging measures.
